STRS Ohio’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

STRS Ohio’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8,400	Closed	-$39K	–	2338
2022 Q1	$39K	Hold	8,400	–	–	﹤0.01%	1978
2021 Q4	$30K	Hold	8,400	–	–	﹤0.01%	2070
2021 Q3	$67K	Hold	8,400	–	–	﹤0.01%	2019
2021 Q2	$95K	Buy	+8,400	New	+$84.3K	﹤0.01%	1986
2014 Q4	–	Sell	-23	Closed	-$35K	–	1818
2014 Q3	$35K	Buy	+23	New	+$33.3K	﹤0.01%	1692
2013 Q3	–	Sell	-96	Closed	-$103K	–	1929
2013 Q2	$105K	Buy	+96	New	+$107K	﹤0.01%	1624

Other funds holding VIRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

STRS Ohio's VIRX Position: Q2 2022 in Review

STRS Ohio sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2022, closing a stake of 8,400 shares — an estimated $39K sold.

STRS Ohio first reported a position in VIRX in Q2 2013 and held it in 6 quarters. The position peaked at $105K in Q2 2013. 63 funds tracked by Wall St. Rank hold VIRX as of Q2 2022.

STRS Ohio reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
STRS Ohio sold 8,400 Viracta Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $39K.
STRS Ohio first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 6 quarters.
STRS Ohio's Viracta Therapeutics, Inc. Common Stock position peaked at $105K in Q2 2013.
63 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2022.

Based on STRS Ohio's 13F filing for Q2 2022, filed 25 Jul 2022.